Lisata Therapeutics Inc (LSTA)

Currency in USD
3.2350
-0.0950(-2.85%)
Real-time Data·
Earnings results expected in 13 days
LSTA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
3.21003.2650
52 wk Range
1.81005.0700
Key Statistics
Prev. Close
3.33
Open
3.265
Day's Range
3.21-3.265
52 wk Range
1.81-5.07
Volume
23.55K
Average Volume (3m)
102.93K
1-Year Change
40.1512%
Book Value / Share
1.68
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
LSTA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
9.5000
Upside
+193.66%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in oversold territory

Lisata Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Lisata Therapeutics Inc Earnings Call Summary for Q3/2025

  • Lisata Therapeutics reported Q3 2025 EPS of -$0.49, beating analyst expectations of -$0.59, but stock fell 7.26% in aftermarket trading to $2.17.
  • Operating expenses decreased 17.3% year-over-year to $4.4 million, with R&D expenses down 22.9% and net losses reduced to $4.2 million from $4.9 million.
  • Despite positive earnings surprise of 16.95%, investor concerns persist about ongoing net losses and the company's ability to secure funding for future trials.
  • Management anticipates upcoming phase 3 trials for sirtepotide and is focused on securing pharmaceutical partnerships to fund clinical programs.
  • CEO Dr. David Mazzo highlighted positive results across various studies, while CMO Dr. Kristen Buck emphasized sirtepotide's ability to modify tumor microenvironments.
Last Updated: 06/11/2025, 22:50
Read Full Transcript

Compare LSTA to Peers and Sector

Metrics to compare
LSTA
Peers
Sector
Relationship
P/E Ratio
−1.8x−2.3x−0.4x
PEG Ratio
−0.09−0.110.00
Price/Book
2.0x1.9x2.6x
Price / LTM Sales
171.9x10.2x3.2x
Upside (Analyst Target)
185.3%69.2%46.7%
Fair Value Upside
Unlock15.6%7.6%Unlock

Analyst Ratings

1 Buy
1 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 9.5000
(+193.66% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Brookline Capital Markets
Hold---Downgrade21/01/2026
H.C. Wainwright
Buy15.00+363.68%-Maintain21/08/2025
Brookline Capital Markets
Buy32.00+889.18%20.00Maintain15/07/2025
H.C. Wainwright
Buy15.00+363.68%-Maintain18/06/2025

Earnings

Latest Release
31/03/2026
EPS / Forecast
-0.34 / -0.63
Revenue / Forecast
100K / --
EPS Revisions
Last 90 days

People Also Watch

2.650
OVID
-1.12%
4.370
TLS
+2.58%
2.615
CDXS
+3.77%
1.2550
SUNE
+1.21%

FAQ

What Is the Lisata Therapeutics (NASDAQ: LSTA) Share Price Today?

The Lisata Therapeutics stock price today is 3.2350 USD.

What Stock Exchange Does Lisata Therapeutics (LSTA) Trade On?

Lisata Therapeutics is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Lisata Therapeutics?

The stock symbol (also called a 'ticker') for Lisata Therapeutics is "LSTA."

What Is the Current Lisata Therapeutics Market Capitalisation?

As of today, Lisata Therapeutics (NASDAQ: LSTA) market cap is 29.2200M USD.

What Is Lisata Therapeutics's (LSTA) Earnings Per Share (TTM)?

The Lisata Therapeutics EPS is currently -1.9093 (Trailing Twelve Months).

When Is the Next Lisata Therapeutics Earnings Date?

Lisata Therapeutics's next earnings report will be released on 07/05/2026.

Is LSTA a Buy or Sell From a Technical Analyst Perspective?

Based on today's Lisata Therapeutics moving averages and other technical indicators, the daily buy/sell signal for LSTA stock is Strong Sell.

How Many Times Has Lisata Therapeutics Stock Split?

Lisata Therapeutics has split 6 times. (See the LSTA stock split history page for full effective split date and price information.)

How Many Employees Does Lisata Therapeutics Have?

Lisata Therapeutics has 21 employees, based on their latest Companies House report.

What is the current trading status of Lisata Therapeutics (NASDAQ: LSTA)?

As of 24/04/2026, Lisata Therapeutics (LSTA) is trading at a share price of 3.2350 USD, with a previous close of 3.3300 USD. The stock has fluctuated within a day range of 3.2100 USD to 3.2650 USD, while its 52-week range spans from 1.8100 USD to 5.0700 USD.

What Is Lisata Therapeutics (LSTA) Price Target According to Analysts?

The average 12-month price target for Lisata Therapeutics is 9.5000 USD, with a high estimate of 15 USD and a low estimate of 4 USD. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +193.66% Upside potential.

Industry Spotlight

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.